- $456.33m
- $558.59m
- $266.27m
Annual income statement for Evolus, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | C2022 December 31st | C2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 56.5 | 99.7 | 149 | 202 | 266 |
| Cost of Revenue | |||||
| Gross Profit | 38.2 | 56.1 | 89.8 | 138 | 182 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 210 | 145 | 214 | 251 | 301 |
| Operating Profit | -153 | -45.4 | -65.3 | -49.2 | -34.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -163 | -46.8 | -74.3 | -61.5 | -49.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -163 | -46.8 | -74.4 | -61.7 | -50.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -163 | -46.8 | -74.4 | -61.7 | -50.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -163 | -46.8 | -74.4 | -61.7 | -50.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.21 | -1.18 | -1.22 | -0.879 | -0.738 |